Is Intuitive Surgical Stock Finally Undervalued?
Intuitive Surgical (NASDAQ:ISRG) is the maker of the well-known da…
Sell
1
BNGO Quote, Financials, Valuation and Earnings
Last price:
$1.77
Seasonality move
:
-29.19%
Day range:
$1.78 - $1.85
52-week range:
$1.50 - $30.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.15x
P/B ratio:
0.18x
Volume:
914.8K
Avg. volume:
868.2K
1-year change:
-92.9%
Market cap:
$8.4M
Revenue:
$30.8M
EPS (TTM):
-$11.39
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bionano Genomics, Inc. has 430.73% upside to fair value with a price target of $9.50 per share.
BNGO vs. S&P 500
-
Over the past 5 trading days, Bionano Genomics, Inc. has underperformed the S&P 500 by -54.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bionano Genomics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bionano Genomics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Bionano Genomics, Inc. reported revenues of $6.7M.
Earnings Growth
-
Bionano Genomics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bionano Genomics, Inc. reported earnings per share of -$1.99.
Enterprise value:
520K
EV / Invested capital:
0.01x
Price / LTM sales:
0.15x
EV / EBIT:
--
EV / Revenue:
0.02x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4M
Return On Assets:
-82.99%
Net Income Margin (TTM):
-271.02%
Return On Equity:
-143.97%
Return On Invested Capital:
-99.52%
Operating Margin:
-115.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $31.5M | $36.6M | $27.4M | $7.8M | $6.7M | |
| Gross Profit | $8M | $10.6M | $1.4M | $2.6M | $3.5M | |
| Operating Income | -$142.6M | -$103.1M | -$55.2M | -$20.3M | -$7.8M | |
| EBITDA | -$130.8M | -$89.7M | -$42.2M | -$17.2M | -$5.5M | |
| Diluted EPS | -$4.84 | -$5.02 | -$11.39 | -$0.24 | -$1.99 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $342M | $216.3M | $122.6M | $60.6M | $42.7M | |
| Total Assets | $356.8M | $321.6M | $271.4M | $129.4M | $76M | |
| Current Liabilities | $10.7M | $27.9M | $33.5M | $37.2M | $24.2M | |
| Total Liabilities | $10.9M | $36.8M | $56.6M | $49M | $30.6M | |
| Total Equity | $345.9M | $284.7M | $214.8M | $80.3M | $45.4M | |
| Total Debt | -- | $10.8M | $10.7M | $27.6M | $19.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$133.1M | -$111.1M | -$26.4M | -$22.4M | -$3.5M | |
| Cash From Investing | $65.7M | $54.3M | -$14.5M | $28.6M | $2M | |
| Cash From Financing | $55.5M | $63.4M | $22.6M | -$534K | $1.5M | |
| Free Cash Flow | -$135.8M | -$112.1M | -$26.4M | -$22.5M | -$3.5M | |
BNGO
Sector
Market Cap
$8.4M
$29.9M
Price % of 52-Week High
5.87%
50%
Dividend Yield
0%
0%
Shareholder Yield
-202.51%
-1.25%
1-Year Price Total Return
-92.9%
-24.69%
Beta (5-Year)
2.252
0.573
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.85
200-day SMA
Sell
Level
$5.54
Bollinger Bands (100)
Sell
Level
2.98 - 4
Chaikin Money Flow
Sell
Level
-799.8K
20-day SMA
Sell
Level
$3.53
Relative Strength Index (RSI14)
Sell
Level
29.99
ADX Line
Sell
Level
32.05
Williams %R
Buy
Level
-92.75
50-day SMA
Sell
Level
$3.36
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Sell
Level
-11.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-15.4435)
Sell
CA Score
(Annual)
Level (-3.2585)
Buy
Beneish M-Score
(Annual)
Level (-6.3731)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.6896)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, BNGO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BNGO average analyst price target in the past 3 months is $9.50.
-
Where Will Bionano Genomics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bionano Genomics, Inc. share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About Bionano Genomics, Inc.?
Analysts are divided on their view about Bionano Genomics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bionano Genomics, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Bionano Genomics, Inc.'s Price Target?
The price target for Bionano Genomics, Inc. over the next 1-year time period is forecast to be $9.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BNGO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bionano Genomics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BNGO?
You can purchase shares of Bionano Genomics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bionano Genomics, Inc. shares.
-
What Is The Bionano Genomics, Inc. Share Price Today?
Bionano Genomics, Inc. was last trading at $1.77 per share. This represents the most recent stock quote for Bionano Genomics, Inc.. Yesterday, Bionano Genomics, Inc. closed at $1.79 per share.
-
How To Buy Bionano Genomics, Inc. Stock Online?
In order to purchase Bionano Genomics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock Undervalued?
Southwest Airlines (NYSE:LUV) has been struggling for multiple years to…
Is ASML Stock Overvalued?
ASML Holding (NASDAQ:ASML) is a Dutch business that designs, manufactures…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 38x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 40x
Alerts
Buy
90
OKLO alert for Sep 22
Oklo, Inc. [OKLO] is up 3.74% over the past day.
Buy
91
BHF alert for Sep 22
Brighthouse Financial, Inc. [BHF] is down 4.22% over the past day.
Buy
78
SMR alert for Sep 22
NuScale Power Corp. [SMR] is down 3.85% over the past day.
